azacitidine has been researched along with Myeloproliferative-Myelodisplastic Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilar, C; Arzuaga, J; Bernal, T; Borrás, J; Brunet, S; Calabuig, M; Calbacho, M; Cedena, MT; Chen, TH; Coll, R; Collado, R; Cortés, M; Díaz-Beyá, M; Fernández, M; García, O; Jiménez, MJ; López-Cadenas, F; Marchante, I; Marco, V; Medina, A; Pedreño, M; Pedró, C; Ramos, F; Ribera, JM; Sanz, G; Simiele, A; Stoica, C; Talarn, C; Triguero, A; Xicoy, B; Zamora, L | 1 |
| Beyne-Rauzy, O; Braun, T; Chait, Y; Chretien, ML; Duchmann, M; Dumas, PY; Fenaux, P; Gruson, B; Guieze, R; Hirsch, P; Itzykson, R; Laribi, K; Legros, L; Micol, JB; Park, S; Pilorge, S; Platzbecker, U; Sahnes, L; Salanoubat, C; Sébert, M; Solary, E; Vey, N | 1 |
| Abou Hussein, AK; Al-Kali, A; Elliott, M; Gangat, N; Hashmi, S; Hogan, W; Litzow, M; Patnaik, M; Zblewski, D | 1 |
| Arnan, M; Duarte, RF; Pomares, H; Sánchez-Ortega, I; Sureda, A | 1 |
| Chang, C; Fei, C; Gu, S; Guo, J; Li, X; Zhang, X; Zhang, Y; Zhao, Y | 1 |
1 trial(s) available for azacitidine and Myeloproliferative-Myelodisplastic Diseases
| Article | Year |
|---|---|
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Prognosis; Survival Rate | 2018 |
4 other study(ies) available for azacitidine and Myeloproliferative-Myelodisplastic Diseases
| Article | Year |
|---|---|
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Topics: Azacitidine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Retrospective Studies | 2022 |
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Survival Analysis; Treatment Outcome | 2017 |
Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Neutropenia; Numbers Needed To Treat; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Triazoles | 2016 |
Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.
Topics: Adult; Aged; Apoptosis; Azacitidine; Bone Marrow Cells; Cells, Cultured; Cytarabine; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Humans; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Survival; Tumor Protein p73; Tumor Suppressor Proteins | 2013 |